Schjoedt KJ - Search Results

1

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH. Schjoedt KJ, et al. Kidney Int. 2006 Aug;70(3):536-42. doi: 10.1038/sj.ki.5001580. Epub 2006 Jun 14. Kidney Int. 2006. PMID: 16775595 Free article. Clinical Trial.

2

Beneficial impact of spironolactone in diabetic nephropathy.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH. Schjoedt KJ, et al. Kidney Int. 2005 Dec;68(6):2829-36. doi: 10.1111/j.1523-1755.2005.00756.x. Kidney Int. 2005. PMID: 16316360 Free article. Clinical Trial.

3

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Rossing K, et al. Among authors: schjoedt kj. Kidney Int. 2005 Sep;68(3):1190-8. doi: 10.1111/j.1523-1755.2005.00511.x. Kidney Int. 2005. PMID: 16105050 Free article. Clinical Trial.

4

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Rossing K, et al. Among authors: schjoedt kj. Diabetes Care. 2005 Sep;28(9):2106-12. doi: 10.2337/diacare.28.9.2106. Diabetes Care. 2005. PMID: 16123474 Clinical Trial.

5

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Schjoedt KJ, et al. Diabetologia. 2004 Nov;47(11):1936-9. doi: 10.1007/s00125-004-1542-0. Epub 2004 Nov 17. Diabetologia. 2004. PMID: 15551047 Clinical Trial.

6

Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.

Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH. Schjoedt KJ, et al. Horm Metab Res. 2005 Apr;37 Suppl 1:4-8. doi: 10.1055/s-2005-861359. Horm Metab Res. 2005. PMID: 15918104 Clinical Trial.

7

Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.

Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH. Schjoedt KJ, et al. Scand J Clin Lab Invest. 2006;66(3):173-80. doi: 10.1080/00365510600548702. Scand J Clin Lab Invest. 2006. PMID: 16714246 Clinical Trial.

8

Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients.

Lajer M, Schjoedt KJ, Jacobsen P, Tarnow L, Parving HH. Lajer M, et al. Among authors: schjoedt kj. Diabet Med. 2006 Jun;23(6):675-80. doi: 10.1111/j.1464-5491.2006.01871.x. Diabet Med. 2006. PMID: 16759311

9

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.

Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH. Persson F, et al. Among authors: schjoedt kj. Kidney Int. 2008 Jun;73(12):1419-25. doi: 10.1038/ki.2008.68. Epub 2008 Mar 12. Kidney Int. 2008. PMID: 18337712 Free article. Clinical Trial.

10

Long-term prevention of diabetic nephropathy: an audit.

Schjoedt KJ, Hansen HP, Tarnow L, Rossing P, Parving HH. Schjoedt KJ, et al. Diabetologia. 2008 Jun;51(6):956-61. doi: 10.1007/s00125-008-0990-3. Epub 2008 Apr 3. Diabetologia. 2008. PMID: 18385971

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page